MRUS
Merus N.V.
Merus N.V. insider trading
Merus N.V. files with the SEC as a Pharmaceutical Preparations company headquartered in 3584 CM Utrecht, DE. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.
From SEC filings
Recent MRUS insider transactions
Merus N.V.'s insiders made no open-market purchases or sales in the company's most recent Form 4 filings — those filings are share grants, option exercises and dispositions back to the issuer, which are compensation rather than decisions. That absence is itself worth knowing: nobody at MRUS spent or raised their own money in the market over this stretch. Two years of open-market trades are below.
SEC Form 4 data, Q3 2024 to Q2 2026
MRUS insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 3 insiders traded MRUS on the open market: 10 purchases worth $234.9M and 10 sales worth $6M, 4 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 10 purchases ($234.9M) and 5 sales ($3.8M), by 3 insiders.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | — | — | |
| Q1 2026 | — | — | |
| Q4 2025 | +$234.9M10 buys | −$959.5K2 sales | |
| Q3 2025 | — | −$2.8M3 sales · all on a plan | |
| Q2 2025 | — | −$1.8M1 sale · all on a plan | |
| Q1 2025 | — | −$194K2 sales | |
| Q4 2024 | — | — | |
| Q3 2024 | — | −$270K2 sales |
- Largest purchase
- +$102.1M of MRUS by Genmab A/s (10% Owner) on Dec 29, 2025.
- Largest sale
- −$1.8M of MRUS by Silverman Peter B. (COO & GC) on Jun 20, 2025, under a 10b5-1 plan.
Open-market transactions through Jun 30, 2026most recent first
Genmab A/s
10% Owner
+$102.1M
Dec 29, 2025
1,052,806 sh · $97.00
Genmab A/s
10% Owner
+$13.8M
Dec 26, 2025
142,610 sh · $97.00
Genmab A/s
10% Owner
+$288.9K
Dec 26, 2025
2,978 sh · $97.00
Genmab A/s
10% Owner
+$9.3M
Dec 24, 2025
96,082 sh · $97.00
Genmab A/s
10% Owner
+$54.4M
Dec 23, 2025
561,042 sh · $97.00
Genmab A/s
10% Owner
+$1.5M
Dec 22, 2025
15,710 sh · $97.00
Genmab A/s
10% Owner
+$6.4M
Dec 19, 2025
66,264 sh · $97.00
Genmab A/s
10% Owner
+$20.6M
Dec 18, 2025
212,177 sh · $97.00
Genmab A/s
10% Owner
+$14.6M
Dec 17, 2025
150,795 sh · $97.00
Genmab A/s
10% Owner
+$11.7M
Dec 16, 2025
120,752 sh · $97.00
Shuman Harry
VP Controller, PAO
−$163.4K
Nov 26, 2025
1,700 sh · $96.10
Shuman Harry
VP Controller, PAO
−$796.1K
Nov 25, 2025
8,300 sh · $95.92
Silverman Peter B.10b5-1
COO & GC
−$1.5M
Jul 17, 2025
25,000 sh · $60.00
Silverman Peter B.10b5-1
COO & GC
−$924.3K
Jul 10, 2025
16,805 sh · $55.00
Silverman Peter B.10b5-1
COO & GC
−$368.2K
Jul 09, 2025
6,695 sh · $55.00
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Dec 29, 2025 | Genmab A/s10% Owner | 1,052,806 | $97.00 | +$102.1M |
| Dec 26, 2025 | Genmab A/s10% Owner | 142,610 | $97.00 | +$13.8M |
| Dec 26, 2025 | Genmab A/s10% Owner | 2,978 | $97.00 | +$288.9K |
| Dec 24, 2025 | Genmab A/s10% Owner | 96,082 | $97.00 | +$9.3M |
| Dec 23, 2025 | Genmab A/s10% Owner | 561,042 | $97.00 | +$54.4M |
| Dec 22, 2025 | Genmab A/s10% Owner | 15,710 | $97.00 | +$1.5M |
| Dec 19, 2025 | Genmab A/s10% Owner | 66,264 | $97.00 | +$6.4M |
| Dec 18, 2025 | Genmab A/s10% Owner | 212,177 | $97.00 | +$20.6M |
| Dec 17, 2025 | Genmab A/s10% Owner | 150,795 | $97.00 | +$14.6M |
| Dec 16, 2025 | Genmab A/s10% Owner | 120,752 | $97.00 | +$11.7M |
| Nov 26, 2025 | Shuman HarryVP Controller, PAO | 1,700 | $96.10 | −$163.4K |
| Nov 25, 2025 | Shuman HarryVP Controller, PAO | 8,300 | $95.92 | −$796.1K |
| Jul 17, 2025 | Silverman Peter B.10b5-1COO & GC | 25,000 | $60.00 | −$1.5M |
| Jul 10, 2025 | Silverman Peter B.10b5-1COO & GC | 16,805 | $55.00 | −$924.3K |
| Jul 09, 2025 | Silverman Peter B.10b5-1COO & GC | 6,695 | $55.00 | −$368.2K |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
Merus N.V. company record
- SEC industry classification
- Pharmaceutical Preparations
- Headquarters
- 3584 CM Utrecht, DE
- Incorporated in
- P7
- SEC Central Index Key
- 0001651311
- Previously filed as
- Merus B.V.
Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.
After insiders bought MRUS
What the stock actually did in the 90 days following each open-market purchase
Don't check MRUS — let it ping you
Get told the moment an insider moves on MRUS
Pro watches Merus N.V. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add MRUS to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.
The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.
How to read MRUS insider activity
- Open-market purchase (code P)
- An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
- Grants and option exercises (codes A, M)
- Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
- Cluster buy
- Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.
Other Health Care tickers
Questions
- Have MRUS insiders bought or sold stock recently?
- No open-market purchases or sales by Merus N.V. insiders appear in the Form 4 filings scanned for this page. Grants, option exercises and tax withholding are not counted as trades.
- How much MRUS stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 3 Merus N.V. insiders made 10 open-market purchases worth $234.9M and 10 sales worth $6M. 4 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: 10 purchases ($234.9M) and 5 sales ($3.8M). The largest purchase was Genmab A/s buying $102.1M on Dec 29, 2025. The largest sale was Silverman Peter B. selling $1.8M on Jun 20, 2025.
- When did an insider last buy MRUS shares?
- The most recent open-market purchase in SEC's data through Jun 30, 2026 is Genmab A/s (10% Owner) buying $102.1M on Dec 29, 2025.
- Where does MRUS insider trading data come from?
- From the Form 4 filings Merus N.V.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.